Daewoong Pharmaceutical rises 7.87% amid COVID-19 (Camostat) theme surge
On the 10th, the COVID-19 (Camostat) theme showed strength by rising 3.05% compared to the previous day, while Daewoong Pharmaceutical, gaining attention as a related stock, surged 7.87% compared to the previous day. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling medicines such as Urusa and Albis.
[Graph] Major stock price changes in the COVID-19 (Camostat) theme

According to the analysis by Thinkpool Robo Algorithm RASSI, Daewoong Pharmaceutical ranked 2nd out of 4 stocks in the quant financial ranking by exceeding the theme’s average scores in growth, stability, and profitability. This can be interpreted as Daewoong Pharmaceutical having relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.
[Table] Top stocks by financial scores within the theme

※ The quant financial scores are results analyzed by the robo algorithm based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.
※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Opening a Bank Account in Korea Is Too Difficult..."It Costs 150,000 Won Just to Open a Child's Account or Check Card" [Foreigner K-Finance Status]②
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.